Biomerica (NASDAQ:BMRA) posted its quarterly earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02), Fidelity Earnings reports. The company had revenue of $1.13 million during the quarter, compared to analyst estimates of $1.53 million. Biomerica had a negative net margin of 19.46% and a negative return on equity of 27.29%.

BMRA traded up $0.02 during trading on Friday, hitting $3.57. The company had a trading volume of 444 shares, compared to its average volume of 7,640. The stock has a market capitalization of $32.01 million, a PE ratio of -32.43 and a beta of -0.64. Biomerica has a 1-year low of $2.60 and a 1-year high of $9.32.

About Biomerica

Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.

Read More: Diversification

Earnings History for Biomerica (NASDAQ:BMRA)

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.